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ABSTRACT  
Osteoarthritis (OA) currently affects 41 million Americans, and knee OA (KOA) 
alone causes the highest risk of mobility disability of any medical condition in people 65 
years and older. There are no current treatments to reverse the degenerative changes of 
KOA, and research is aimed at finding biomarkers of KOA progression to aid in the 
development of effective therapies.   
Osteophytes are a hallmark feature of KOA and may act as a biomarker of joint 
space loss and pain progression. MR imaging, which is an accurate and non-invasive 
method to monitor KOA disease status, may aid in clarifying the role of osteophytes in 
KOA, especially using semi-automated quantitative software methods to accurately and 
efficiently calculate osteophyte volume in longitudinal studies.  
This study investigated the association of osteophyte volume change with joint 
space narrowing and pain progression in a randomized sample of 505 subjects from the 
FNIH OA Biomarker Consortium Project, a case-control study based on a larger 
    vi 
longitudinal study of patients with KOA. We also aimed to further validate a software 
method that measured osteophyte volume in MRI.   
We found a moderate and significant association with osteophyte volume and 
joint space narrowing, but no significant association with pain progression. The software 
was further validated as responsive and efficient method to measure KOA osteophyte 
volume change.  
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1.a. Osteoarthritis: overview  
There are an estimated 41 million Americans affected by osteoarthritis (OA), and 
societal trends in the population indicate the number of people affected by OA will 
increase by 50% of the next 20 years, partially due to an increase of obesity rates 
(Johnson & Hunter, 2014). Currently, OA is one of the leading causes of disability 
among non-institutionalized adults, with symptomatic OA affecting 10% of the adult 
population in the US, and knee OA (KOA) alone causing the highest risk of mobility 
disability of any medical condition in people 65 years and older (Johnson & Hunter, 
2014). 80% of patients with OA have some limitation of mobility, while one-fourth 
cannot perform major activities of daily living (Guccione et al., 1994).   
Economically, OA costs the US over $100 billion annually in direct and indirect 
costs (Lozada, 2015). In severe cases of knee or hip arthritis, total knee replacements 
(TKRs) or total hip replacements (THRs) are required, signaling the end-stage of the 
disease. OA is indicated in 95% of TKR and THR procedures, costing over 42 billion 
dollars in hospital expenditures in 2009 (Murphy & Helmick, 2012). Mortality from other 
diseases is also affected. Compared to the general population, adults with OA have nearly 
a twofold increase in mortality from cardiovascular disease and dementia (CDC, 2015).   
Given the high individual and societal disease burden, research into OA is a high 
priority. OA, or degenerative joint disease, is defined as progressive, focal loss of joint 
hyaline cartilage with associated bony changes (Medline, 2016). The most commonly 
affected areas are the knee, hip, and hand joints. Biologically, the process of OA involves 
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the gradual loss of articular cartilage, narrowed joint space, the growth of bone spurs 
called osteophytes, and nonspecific synovial inflammation. In patients, OA is diagnosed 
by structural signs (e.g. radiographic evidence of joint space narrowing, osteophytes, and 
bony sclerosis) and clinical symptoms (e.g. pain, swelling, and stiffness) (CDC, 2015).  
This study will focus on knee OA, or KOA.  
The knee, defined as the area where the femur in the upper leg meets the tibia on 
the lower leg, actually contains two joints: the tibiofemoral joint and the patellofemoral 
joint, which work together to form a modified hinge joint that can bend and rotate slightly 
(Figure 1). Given that our knees support 1.5 times our body weight when we walk and 8 
times our body weight when we squat, these joints bear enormous pressure loads  
(Schmidler, 2016).   
The points where the bones touch each other are covered with articular cartilage 
(i.e. hyaline cartilage), a smooth connective tissue that allows the bones to move freely 
against each other. It is in this tissue where the main degeneration of KOA occurs. 
Articular cartilage is found on the ends of the femur, the top of the tibia, and on the back 
of the patella. Against the articular cartilage of the femur and tibia are the crescent-
shaped menisci, which act as shock absorbers that spread weight-bearing force over a 
larger area (Schmidler, 2016). Menisci are also affected by KOA. Finally, surrounding 
these cartilaginous structures is the joint capsule, containing outer fibrous capsule layer 
and the inner synovial layer, held together by ligaments. The synovium produces synovial 
fluid that provides lubrication for the knee.   
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KOA is the result of the wearing-down of the articular and meniscal cartilage on 
either knee joint, although most research is focused on the weight-bearing region of the 
tibiofemoral joint. Cartilage at pressure points wears down over time and has limited 
repairing ability due to its lack of blood vessels and very low cell proliferation rate. This 
is the root of the problem of any type of OA: once damage is done to the cartilage, there 
is currently no effective way to reverse it.   
  
Figure 1. Healthy knee and osteoarthritic knee structures. KOA is characterized by a 
thickened and stretched capsule, worn down cartilage, osteophyte growth, a thickened and 
inflamed synovium, narrowed joint space, and thinner bone. (Bupa, 2015)  
  
In broad strokes, the course of KOA starts with worn down cartilage that leads to 
a narrowed joint space width (JSW), or as it is sometimes called, joint space loss (JSL) or 
joint space narrowing (JSN). This injury causes inflammation of the synovium and 
capsule, bony outgrowths at the joints called osteophytes, and in severe cases, the damage 
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to the femoral or tibial bone structures (Figure 1). Both local and systemic factors 
contribute to the development of KOA. Local factors include injuries to the knee and 
developmental disorders that affect the musculoskeletal system, such as congenital hip 
dysplasia (Baker-LePain et al., 2010). Systemic factors include older age, obesity, gene 
polymorphisms such as COL2A1 that code for a type of collagen in bone, and decreased 
estrogen levels, leading to a higher incidence of OA in post-menopausal women  
(Hämäläinen et al., 2009, Roman-Blas et al., 2009).  
   
1.b. Development of OA  
Development of OA is progressive due to the poor ability of cartilage to self-
repair. The etiopathogenesis can be divided into three stages: stage I, normal cartilage; 
stage II, aging/damaged cartilage; and stage III, osteoarthritic cartilage (Cannon, 2001). 
In stage I, normal cartilage is characterized by chondrocytes that maintain an 
extracellular matrix (ECM) with strong tensile strength. This healthy ECM contains 
molecules such as collagens type II, IX, and XI, proteoglycans such as aggrecan, and 
glycosaminoglycans like chondroitin sulfate and keratan sulfate, all of which retain water 
and form the biomechanical basis of articular cartilage’s load-bearing capacity (Fox et al., 
2009). Incidentally, some of these molecules are being investigated as possible clinical 
therapies. (Uebelhart et al., 2004; Pomin, 2015),    
Chondrocytes, the cells of the articular cartilage, maintain the ECM by balancing 
the rate of synthesis and degradation of the structural components. Degradation is 
accomplished by chondrocyte secretion of matrix metalloproteinases (MMPs), which are 
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enzymes that degrade ECM components (Cannon, 2001). Synthesis is promoted by the 
secretion of tissue inhibitors of MMPs (TIMPs), which in turn are upregulated by 
proinflammatory factors such as interleukin-1 (IL-1) and tumor necrosis factor-ɑ (TNF-ɑ) 
(Cannon, 2001). Also, synthesis is promoted by growth factors such as transforming 
growth factor (TGF)-β and bone morphogenetic proteins (BMPs), which are among the 
same factors responsible for endochondral ossification during fetal development (Sandell 
and Aigner, 2001).   
Stage II, the passage of normal cartilage into aging/damaged cartilage, is caused 
by the failure of chondrocytes to maintain appropriate turnover of ECM components 
necessary to compensate for the joint’s mechanical stresses, instability, or matrix 
destruction (Cannon, 2001). Initiating variables include decreased ligament stability, 
excessive weight-bearing forces, decreased peripheral neuroprotective responses over 
time, and increased microfractures in the subchondral bone, for instance from a knee 
injury (Lane Smith et al., 2000). Subchondral microfractures are especially relevant to 
osteophyte development, since increased cartilage degeneration causes the development 
of a subchondral sclerosis zone, which may progress into osteophyte growth (Cannon, 
2001).   
Sandell and Aigner describes five categories of cellular reaction patterns to the 
osteoarthritic disease process, as seen in Figure 2: 1) proliferation and cell death 
(apoptosis), 2) changes in synthetic activity, 3) changes in degradation, 4) phenotypic 
modulation of the articular chondrocytes, and 5) formation of osteophyte (2001).   
6  
First, a low level of chondrocyte proliferation is a distinctive hallmark of OA, 
since normal chondrocytes very rarely regenerate. Some apoptosis occurs as well, 
although rates of cell death are still undetermined. Second, chondrocytes increase their 
synthesis of ECM components, but paradoxically, a net loss of PG content is one of the 
hallmarks of the entire OA cartilage degeneration process.   
Third, chondrocytes increase their synthesis of degradative enzymes, particularly  
MMPs. Nearly all OA cells were found to contain elevated levels of MMP-3, 8, and 13. 
Fourth, chondrocytes change their phenotype by dedifferentiating to an early, fibroblast-
like cell type, which synthesizes different types of ECM that do not help the growth of 
healthy adult cartilage. Functional chondrocytes produce collage type II and aggrecan, 
while dedifferentiated chondrocytes produce collagens type I and III. Finally, osteophytes 
develop, which will be described in the next section.  
  
Figure 2: Chondrocyte response to injury. a) Types of injuries and responses. b) Chondrocyte 
modulation of gene expression resulting in recapitulation of collagen production found during 
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development, dedifferentiation of fibroblasts, cartilage growth plate hypertrophy, apoptosis, or 
regeneration of mature cartilage. (Sandell and Aigner, 2001)  
  
1.c. Osteophytes  
Osteophytes are one of the most visible diagnostic features of OA on radiographs, 
and the most common MRI-detected knee abnormality found in non-diagnosed adults 
over the age of 50 (Guermazi et al., 2012).  
Osteophytes develop from new cartilage and bone growth on joint margins. They 
may form independently of OA due to normal aging or other types of disease (Cedars 
Sinai, 2016). For example, osteophytes can form in the back of the spine as a person ages, 
and may be asymptomatic or only cause pain if they impinge on a nerve. Diffuse 
idiopathic skeletal hyperostosis can cause bone ossification along the spine that has the 
appearance of “melted wax” (Ghosh et al., 2004). However, osteophytes are the main 
feature of OA that distinguishes it from other arthritic diseases (Sandell & Aigner, 2011).  
In the knee, it is theorized that osteophytes form to stabilize the joint by 
increasing bone surface area, distributing pressure more evenly across the bone and 
overcoming abnormal cartilage loading (Felson et al., 2005). Studies have demonstrated 
that, after an induced anterior cruciate ligament (ACL) tear, osteophytes form in a way 
that limits pathological translocation of the femur on the tibia, compensating for ligament 
damage (Felson et al., 2005). Osteophytes also form near sites of KOA cartilage loss 
(Felson et al., 2005). However, it is still unclear if osteophyte formation after OA 
progression is related to the disease process, or if it is a marker for nearby cartilage loss.  
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One aim of this study is to examine a possible correlation between osteophyte volume 
change and JSL in subregions of the knee.  
The development process of osteophytes is also still not fully clear, although 
animal and histological studies have illuminated crucial stages. Osteophytes are defined 
as fibrocartilage-capped bony outgrowths arising in the connective tissue overlying the 
bone, the periosteum (van der Kraan et al., 2007). Osteophytes develop in a process 
similar to endochondral ossification, and mesenchymal stem cells are thought to be the 
main cellular precursors of osteophytes (van der Kraan et al., 2007). In a murine model of  
OA, osteophytes formed after repeated injections of TGFB-1 in the knee (Menkes and 
Lane, 2004).   
Figure 3 shows a histological cross-section of a murine experimental model for 
KOA, with major areas of marginal osteophyte formation located at the lateral and medial 
articular surfaces of the tibia and femur (van der Kraan et al., 2007). Osteophytes may 
also form in other locations, for instance at the site of attachment of the joint capsule or 
ligaments (i.e. enthesophytes), but in this study we focus on marginal osteophyte growth.  
Although osteophytes are hypothesized to stabilize OA knees, they are still 
associated with worse JSW (Muraki et al., 2011; Felson et al., 2005), increased pain 
(Sowers et al., 2011), and decreased physical functioning (Muraki et al., 2011). This is 
why it is crucial to clarify the association of osteophytes to KOA, as we attempt to do in 
this study by following volumetric osteophyte change in a longitudinal study.  
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Figure 3. Histological schematic of a murine knee joint. Stars mark areas where osteophytes 
develop during experimental OA. T – tibia, P – patella, F – femur, L – ligament, M – meniscus, 
C – capsule. (van der Kraan et al., 2007)  
  
1.d. Pain  
One of the key clinical outcomes of KOA is pain. A specific grading scale, the 
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a 24-item 
index used to assess pain, stiffness, and physical function in patients with KOA or hip 
OA (Bellamy, 2002). The domain scores range from 0 to 20 for pain, 0 to 8 for stiffness, 
and 0 to 68 for physical function (Bellamy, 2014).  Pain is based on patient descriptors of 
pain level during five activities: walking, using stairs, sitting in bed, lying in bed, and 
standing (Bellamy, 2014).   
While it may seem straightforward to correlate the severity of the disease with the 
severity of pain, almost half of people with knee pain have no radiographic OA 
10  
(Guermazi et al., 2012). Conversely, patients with diagnosable KOA features such as 
cartilage defects may not report any pain (Sowers et al., 2011).   
Nonetheless, it is valuable to investigate if and which biomarkers have a greater 
correlation with higher WOMAC pain scores, given the clinical significance of joint pain 
on disability and quality of life (Muraki et al., 2011). With the availability of clinical 
Osteoarthritis Initiative (OAI) data, a longitudinal cohort study of KOA, we have an 
opportunity to investigate a connection between pain scores and osteophyte size.  
The conception of pain itself is a complex neurological process that can be 
influenced by depression, gender, race, and education (Sharma, 2016). Pain is sensed 
peripherally by nocireceptors, and although articular cartilage does not contain 
nocireceptors, adjacent structures such as the bone, meniscus, and fat pad are innervated 
and respond to tissue damage (Jones et al., 2013). Certain symptoms of KOA are more 
strongly associated with knee pain: BMLs, cartilage defects, osteophytes, and 
synovitis/effusion, which indicates local inflammation (Jones et al., 2013). On the other 
hand, there has been generally consistent evidence that knee bone size, subchondral bone 
density, and meniscal extrusion are not associated with pain (Jones et al., 2013).  
On a more systemic level, obesity is a very strong correlate of knee pain, with 
BMI contributing 10-25% of the increase in knee pain in participants of a 20-year KOA 
research study (Jones et al., 2013). Weight loss is often recommended as part of a 
treatment plan for KOA, although weight gain is more strongly associated with 
worsening pain than weight loss with improvements in pain, suggesting limited 
reversibility of symptoms (Jones et al., 2013).  
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Finally, pain perception differs among individuals based on peripheral and central 
nervous system differences. A lower pressure-pain threshold was associated with pain 
severity but not OA presence, severity, or duration, so pain experience and KOA disease 
trajectories do not always align (Sharma, 2016). Depression is often linked to pain 
experiences for all rheumatic disease, higher self-efficacy is inversely correlated with 
KOA pain, and a tendency to catastrophize (viewing a situation as considerably worse 
than it is) is positively associated with pain severity, possibly explaining the higher pain 
levels reported by women (Jones et al., 2013). Knee pain is heritable as well, with a 
variant in PCSK6 associated with protection against pain in KOA (Jones et al., 2013).  
Isolating the role of osteophytes in KOA pain severity has been difficult, 
especially since studies often use composite scores such as the K/L scale, masking the 
effects of individual symptoms.   
  
1.e. KOA biomarkers and clinical treatment  
Ultimately, one of the key objectives in KOA research is finding biomarkers that 
predict who is at higher risk of developing the disease or having a more severe disease 
sequelae, with hopes of discovering clinical interventions that target earlier stages of the 
disease. The KOA disease process may begin 20 years before JSN is clinically detectable, 
and much earlier molecular and preradiographic biomarkers are detectable before 
radiographic evidence indicates the presence of disease (Figure 4). By the time visible 
JSN structural changes occur, KOA is, at the time of publication, irreversible due to the 
articular cartilage’s inability to regenerate (Sharma, 2016).  
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Figure 4: Timeline of OA symptom onset. OA disease process begins 20 years before JSN is 
detectable. First, molecular biomarkers are detectable serologically, then clinically detectable 
biomarkers, which include preradiographic (MRI, ultrasound, and bone scan) and radiographic 
signs of joint structural changes. End-stage of disease occurs with joint death and replacement.  
(Hunter et al., 2013)  
Clinical treatment currently focuses on pain management and maintenance of 
function. Examples include intraarticular injections of hyaluronic acid, glucosamine 
sulfate, physical therapy, NSAIDs, and arthroplasty (Cannon, 2001).   
Research into clinical disease modifying OA drugs (DMOADs) are looking to 
reduce structural pathology of joint tissue in conjunction with beneficial clinical 
outcomes (Eckstein et al., 2014). In particular, imaging methods such as radiography and 
MRI are important ways to find and monitor structural pathology, so improving imaging 
methodology and utilizing imaging results is a promising avenue of research into KOA 
mechanisms and therapies.  
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2.a. Imaging: overview  
Medical imaging visualizes interior structures of the body for diagnosis and 
treatment, and its major forms include x-rays (a.k.a. radiography), computed tomography 
(CT) scans, magnetic resonance imaging (MRI) scans, and ultrasound. Clinical 
monitoring and research on KOA has mainly used radiography and MRI as imaging 
modalities, although CT scans may be used on patients who cannot tolerate MRI 
(Medscape, 2016). MRI offers the benefit of 3-dimensional imaging, visualization of 
detailed soft tissue structures, and no x-ray radiation hazards.  
An overview of magnetic resonance imaging (MRI) is useful for our discussion of 
KOA imaging. In a body, hydrogen protons are found in fat and water, where they spin 
on an axis to produce a north-south pole like a bar magnet In an MRI scanner, a strong 
magnetic field (usually 1.5- 3 T) aligns the protons’ axes and produces a magnetic vector 
along the MRI axis (Berger, 2002). Receiver coils detect the emitted signal and the signal 
intensity is plotted on a grayscale, creating the MRI scan.  
However, image contrast needs differ based on which tissue is being visualized. 
Using different parameters, MRI scans can emphasize certain tissues (e.g. cartilage or 
bone for musculoskeletal imaging) or suppress the signal from other tissues (e.g. fat). 
This is especially important for MR imaging for KOA, given the range of 
musculoskeletal tissues involved in the disease.  
  
2.b. KOA imaging and grading systems  
In KOA, both soft and hard tissue structures are important to visualize.  
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Radiographs are the cheaper, more common method of detecting and assessing change 
KOA, and features such as JSW, sclerosis, and osteophytes are visible, as seen in Figure  
5.   
MRI scans, while more expensive, allow for cartilage and soft tissue visualization, 
so that features such as cartilage defects and BMLs are only observed through MRI 
scans. Compared to the 2-dimensional imaging of x-rays, a 3-dimensional view of the 
joint structure can be invaluable. Radiographs are also projection images that are 
dependent on position, which could cause inconsistent osteophyte imaging. MR imaging 
has been shown to accurately assess long-term KOA structural changes in dog 
experimental models (Boileau et al., 2008). Also, MRI scans may find JSN that 
radiographic images cannot (Howell, 2010). Figure 6 shows a clinical case in which a 
patient over 40 presented with cartilage loss in a knee despite being diagnosed with 
normal JSW with a radiograph (Howell, 2010). This changed the orthopedist’s treatment 
recommendation and prevented an unnecessary arthroscopic surgery to fix the meniscal 
tear, which turned out not to be the source of the patient’s pain.   
  
Figure 5: Radiograph of an osteoarthritic tibiofemoral knee joint. The joint shows the 




Figure 6: MRI of an osteoarthritic tibiofemoral knee joint. This joint shows a medial view of 
a degenerative meniscal tear, mild cartilage loss, and subchondral fracture from avascular 
necrosis. (Howell, 2010)  
  
With these imaging modalities come grading systems that allow objective 
assessments of disease presence and progressions. KOA grading systems are scales that 
assess the severity of the disease. The most common clinically used systems are 
qualitative and ordinal; for example, grading the severity of KOA from a scale of 0-4. 
Newer grading systems have been developed to take advantage of computer-assisted 
quantitative measurements, where factors like JSW are measured as continuous variables.   
The first and most established grading system is the Kellegren-Lawrence (K/L) 
grading scale, proposed in 1957 and still used as the “gold standard” for KOA diagnosis. 
It uses knee radiographs to observe the presence of four main KOA features. The grades 
range from 0, a knee with no radiographic features of KOA, to 4, where the knee contains 
large osteophytes, marked JSN, severe sclerosis, and definite bony deformity (Kellegren,  
1957).  
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Grading scales can isolate the progression of specific KOA symptoms. One 
limitation of the K/L scale is the inability to individually assess the severity of KOA 
features. This was addressed by Osteoarthritis Research Society International (OARSI), 
which created a radiographic atlas that allows osteophytes and JSN to be separately 
assessed in the medial and lateral tibiofemoral compartments (OARSI, 2001).   
Other scales measure different imaging modalities. Of interest to this thesis are 
the MRI grading scales, which focus on KOA features and subregions (Table 1). They 
include Whole-Organ Magnetic Resonance Imaging Score (WORMS), Knee  
Osteoarthritis Scoring System (KOSS), Boston Leeds Osteoarthritis Score (BLOKS), and  
MRI Osteoarthritis Knee Score (MOAKS) (Kornaat et al., 2005, Hunter et al., 2008,  
Hunter et al., 2011, Peterfy et al., 2005).   
 
  
Table 1: Summary of KOA whole joint semiquantitative MRI scoring systems. These include 




2.c. KOA semi-automated quantitative MRI software  
Given the thousands of MRI scans that may need to be analyzed in a single KOA 
study, it can be difficult for an expert reader such as a radiologist to complete data 
collection within a reasonable amount of time. Qualitative WORMS, KOSS, BLOKS, 
and MOAKS scoring systems are thorough, but require evaluation of 8+ KOA features 
within a whole knee joint scan. Although they are more specific than grading systems 
(such as the K/L) that subsume all KOA features into one score, current qualitative MRI 
grading systems still grade based on an ordinal rather than continuous scale. Also, 
grading may be affected by reader bias.  
The introduction of software able to automate this process is a crucial addition to 
keeping KOA research inexpensive and responsive, as well as allowing the measurement 
of continuous variables such as cartilage and osteophyte volumes. Semi-automated 
software is based on algorithms that do the bulk of the measurements (for instance, by 
detecting the bone-cartilage border based on grayscale values), requiring only a trained 
reader to fine-tune the measurements. A radiologist completes the process with a final 
quality assurance step. Multiple software methods have been developed to measure 
cartilage loss, BML volume, and osteophyte volume in KOA (Iranpour-Boroujeni et al.,  
2011; Duryea et al., 2014; Hakky et al., 2015; Stehling et al., 2011).  
 
Specific aims  
One objective of this study is to validate the responsiveness of a software method 
that calculates marginal osteophyte volume in subjects with diagnosed KOA. Previous 
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studies show that this software demonstrates good inter- and intra-reader reliability, 
strong responsiveness to average change in osteophyte volume over time, and concurrent 
validity with the MOAKS osteophyte score (Hakky et al., 2015). With the addition of 
datasets of 505 patients from the Osteoarthritis Initiative (OAI), a prospective cohort 
study of men and women at risk of KOA or with symptomatic KOA, we are now able to 
reexamine the responsiveness of this software to osteophyte volume measurement.   
This study will also aim to use these osteophyte volume measurements to 
investigate possible associations with cartilage degeneration and pain scores. Since these 
are both clinically important factors of KOA progression and impact patient quality of 
life, finding a significant correlation could allow osteophytes to serve as an imaging 
biomarker for clinical, research, and therapeutic KOA research.  
     
1. To further validate the responsiveness of semi-automated software for measuring 
osteophyte volume change  
2. To examine a possible association between KOA marginal osteophyte volume 
change and JSW over 24 months  
3. To examine a possible association between KOA marginal osteophyte volume 
change and pain over 24 months  
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METHODS  
Study sample  
We assessed knee MRI scans from the Foundation for the National Institutes of  
Health (FNIH) OA Biomarker Consortium Project dataset, drawn from the larger  
National Institutes of Health (NIH) Osteoarthritis Initiative (OAI) study (UCSF, 2013). 
The OAI is a public domain, longitudinal observational study aimed to help researchers 
understand incident and progressional KOA. 4,796 men and women ages 45-79 were 
enrolled from February 2004 to May 2006, recruited based on their symptomatic disease 
status or high risk of developing KOA. The seven-year project maintains a database of 
clinical evaluation data, radiological images, and biospecimens from the OAI participants 
over four years of follow-up. Annual visits every 12 months, were completed through 48 
months, with two additional time points at 72 and 96 months.   
The FNIH OA Biomarker Consortium Project is a separate public-private 
research partnership that uses data from the first four years of the OAI, using a nested 
case-control study (194 cases and 406 controls) to determine the validity and 
responsiveness of biomarkers with KOA progression (Nevitt, 2015). KOA progression 
was measured based on radiographic (x-ray) and pain progression outcomes from 
baseline (BL) compared to 24 month through 60 month OAI clinic visits. Imaging and 
biochemical marker changes were examined between BL and 12 month through 24 
month visits.   
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X-ray progression was defined as medial minimum JSW loss (JSL) that was ≥0.7 
mm from BL to 24, 36 or 48 months. This was the study-specific smallest detectable 
change determined from OAI images (Nevitt, 2015). Subjects with lateral  
KOA JSN at BL were excluded.  
Pain progression was defined as a persistent increase in the total WOMAC pain 
score above the minimal clinically important difference (MCID), compared to BL (Angst 
et al., 2001). The MCID WOMAC pain score is ≥9 change on a 0-100 scale, since it is 
the score associated with the smallest detectable difference (SDD) in patient outcomes 
(Angst et al., 2001). All eligible knees started at a K/L score of 1-3 at BL.  
Subjects were divided into four case-control groups based on x-ray and pain 
progression (Figure 7). The primary case definition was 1) an x-ray + pain (or JSL-only, 
as used in this thesis) progressor, characterized by a knee that had both radiographic and 
pain progression. The primary control definition was a knee that did not reach criteria for 
both endpoints, leading to three control groups: 1) an x-ray-only progressor, 2) a pain-
only progressor, and 3) a non-progressor, defined as a knee with neither X-ray nor pain 
progression. The case-control groups were also frequency matched based on baseline 
BMI and K/L grade, creating a better balance among the groups for covariate adjustment.  
 
Figure 7: FNIH OA Project study sample. This figure displays the selected subjects and total 
number of (knees). Case group: 1) X-ray + pain progressors (n = 194). Control groups: 2) Xray-
only progressors (n = 103), 3) pain-only progressors (n = 103), and 4) non-progressors (n = 200). 
(Nevitt, 2015)  
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In this study, we randomly selected 505 subjects from the 600 subjects in the  
FNIH Study. Our study sample was distributed as JSL + pain progressors (n = 
140),  
JSL-only progressors (n = 97), pain-only progressors (n = 88) and non-progressor 
(n = 180). An earlier preliminary analysis with this software method was done using 289 
FNIH Study subjects and showed statistically significant results (Yin 2016).  
Table 2 and 3 summarize the baseline subject and knee characteristics of the 
participants selected for the FNIH Study.  
 
Table 2: Baseline subject characteristics. Age, gender, race, pain medication usage in the past 




Table 3: Baseline index knee characteristics. History of knee injury (*based on self-report of 
knee injury causing difficulty walking for >=2 days), WOMAC score, and presence of grade 2 
medial JSN (vs. grade 0-1). (Nevitt, 2015)  
  
MRI  
Double echo steady state (DESS) 3D sagittal images were obtained and 
reformatted into a coronal series (0.365 mm x 0.7 mm, 0.73 mm slice thickness) for 
osteophyte readings.  
  
Osteophyte measurements  
Osteophyte volume was measured at four central weight-bearing regions:  
medial femoral condyle (MF), medial tibial plateau (MT), lateral tibial plateau (LT), and 
lateral femoral condyle (LF). The readers viewed and analyzed the scans paired for BL 
and 24-month follow up, but blinded to order of visit and case-control status. A 




Figure 8. Screen capture of the semi-automated quantitative software used to measure 
osteophyte volume. The bone outline is automatically detected with an algorithm, while a reader 
creates the lines closing off the osteophyte areas. Corner #0 = MF, #1 = MT, #2 = LF, #3 = LT.  
  
       Figure 8 shows a screen capture of a single slice that is fully “segmented” 
(i.e. outlined) by a reader. Two readers, a post-doctoral senior radiology resident and a 
research assistant, were trained in the use of the software and assessed for inter- and 
intra-reader reliability. A previous study found reader reproducibility high, with an 
intraclass correlation coefficient (ICC) of 0.98 and an inter-reader ICC of 0.97 (Hakky et 
al., 2015).   
A reading began with locating the standardized starting point on the image, 
roughly within a 2.5 cm region anterior to the intercondylar line. At this point, the 
femoral condyles are no longer separate bony structures (Figure 9). This slice was 
marked the starting point of the series of 18 that were analyzed.   
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Figure 9: Example of a starting point for osteophyte segmentation. The femoral 
intercondylar notch is visible and continuous in coronal section. Marginal osteophyte volumes 
are measured at the femoral and tibial articular surfaces within 2.5 cm anterior to this point, i.e. 
within 18 slices.  
  
We limited measurements to 2.5 cm anterior of the intercondylar line rather than 
the whole tibiofemoral joint, since previous studies have shown this is the crucial weight-
bearing area and a reliable assessment of KOA effects on the joint (Glaser et al., 2003). 
Limiting osteophyte volume measurements to 18 slices ensures a fast reading time, 
roughly 10 minutes per reader, without sacrificing precision (Hakky et al., 2015).  
Next, a second slice was located 17 slices anterior to the first slice at the 
intercondylar line. The joint margin was also found, indicating the location of the soft 
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tissue adjacent to the bone. Each tibiofemoral joint compartment was then measured 
separately. As shown in Figure 9, the knee joint was divided into four compartments 
(“corners”) for separate analysis. Corner #0 was located the MF, corner #1 at the MT, 
corner #2 at the LT and corner #3 at the LF.  
Figure 10 shows the software graphical user interface (GUI) for segmenting 
corners. Once the first and second slices are marked for a corner, the software runs an 
edge detection algorithm that delineates the bone edges by differentiating structures 
along a gray-scale gradient. Bone is darkest, while cartilage and fluid are a few of the 
lightest areas. If a given bone edge contains an osteophyte, the reader will “close it off” 
by drawing a line along the assumed bone contour, isolating the osteophyte area for the 
final volume calculation (Figure 10). This process is repeated for the next 17 slices, then 
for the other three knee joint compartments. Finally, the software measures the total 
osteophyte volume in each region as a sum of the osteophyte areas on all 18 slices.  
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Figure 10: Software GUI. The corners outlined in yellow are completed; osteophytes 
are segmented in corner #0 and #1. The corner outlined in light blue is being edited by the user. 
On the bottom of the screen, “Quit” leaves the GUI, “Prev” navigates to the previous slice, “<” 
and “>” adjusts the blue outline by increasing or decreasing the threshold sensitivity for 
greyscale, and “Hide” temporarily removes the GUI to show the original scan.  
  
Readers were blinded to case-control status and time point. Each scan was 
segmented for osteophytes at one time point, made into a duplicate image, and shown as 
a side-by-side image with image from a second time point, also segmented, to ensure 
consistency. Finally, a radiologist performed a quality assurance step.  
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Statistical analysis  
For each subject group (JSL+pain, JSL-only, pain-only, and non-progressor), we 
analyzed the mean osteophyte volume change from baseline to 24 months (ΔV) and 95% 
confidence interval (95% CI) for the entire knee. We then found the ΔV, standard 
deviation for ΔV (SD), and standardized response mean (SRM) for each anatomical 
region (MF, MT, LT, LF), as well as the medial compartment (M =  MF+MT), lateral 
compartment (L = LF+LT), femoral compartment (F = LF+MF), and tibial compartment 
(T = LT+MT), and total knee (Total = MF+MT+LF+LT).   
 SRM defines the responsiveness of the software to change to osteophyte volume 
measurement, assuming that osteophytes increase in volume over time. It is calculated by 
mean of ΔV divided by the standard deviation of ΔV (ΔV/SD), and reflects the 
sensitivity of a measurement instrument to detect change within groups between two 
points in time (i.e. responsiveness) (Middel and van Soderen, 2002). This calculation acts 
as an effect size index (ES), where thresholds can be interpreted as follows (Middel and 
van Soderen, 2002):  
[1] SRM < 0.20 = trivial   
[2] 0.20 ≤ SRM < 0.50 = small  
[3]  0.50 ≤ SRM < 0.80 = medium   
[4] SRM ≥ 0.80 = large   
Finally, we found with odds ratio (OR) and 95% CI for case/control predictors, 
comparing the relative odds of osteophyte volume change given the exposure (JSL + 
pain, JSL-only, and pain-only). For adjusted ORs, we used logarithmic regression with 
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univariate models, adjusted for covariates of baseline age, sex, BMI, race, K/L grade, 
WOMAC pain score, pain medication use, and minimum JSW. This allows a comparison 
of osteophyte volume change between three separate case/control status groups:   
[1] primary case/control analysis: radiographic + pain progressors (JSL+pain) 
versus non radiographic + pain progressors (all other groups)  
[2] radiographic progressors (JSL+pain and JSL) versus non radiographic 
progressors (pain only and non-progressor)  
[3] pain progressors (JSL+pain and pain only) versus non pain progressors (JSL 
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RESULTS  
  Results are shown in Table 4 - 6. Table 4 is summary of whole knee 
osteophyte volume changes over 24 months, showing the sample size, ΔV, and 95% CI 
for each subject group. Average reader time was 10 minutes.  
 
Table 4: Average osteophyte volume change and 95% confidence interval for total knee, by 
group.  
  
  Several trends are of interest. First, as explained earlier, subject groups 
had different sample sizes, but effects are significant and trends follow the findings 
described in this section (Yin 2016).   
Second, both JSL groups showed a significant higher volume change (JSL+pain 
ΔV = 118.1 mm3, JSL-only ΔV = 132.2 mm3) than non-JSL groups (pain-only = 37.6 
mm3, non-progressor = 41.5 mm3). This was the main finding in the preliminary 
investigation into this cohort.  
Third, pain-only progressors showed the least osteophyte volume change, which 
followed initial findings that showed low to no association of osteophyte growth with 
pain (Yin et al., 2016). This result could support the hypothesis that osteophytes stabilize 
knee by redistributing irregular forces caused by articular cartilage loss.  
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Table 5 shows ΔV, SD, and SRM for each knee region and compartment, divided 
by subject group. The first column displays results for all the groups combined, while the 
next four columns show results for the four case-control groups.  
  
  
Table 5: Average osteophyte volume change, standard deviation, and standardized response 
mean for each knee region and compartment, by group.  
 
   There are several trends in this table:  
[1] JSL groups versus non-JSL groups: again, the trend of increased ∆V in JSL 
groups compared to non-JSL group is reflected in almost every anatomical region 
and compartment for each case/control group. The JSL groups also had a higher 
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average SRM (SRM = 0.42 – 0.75) compared to non-JSL groups (SRM = 0.10 – 
0.45), implying that the software had higher responsiveness to osteophyte volume 
change in groups that showed structural cartilage loss.   
[2] Pain groups versus non-pain groups: pain groups in general showed lower ∆V 
compared to non-pain groups as well as lower responsiveness (e.g. JSL-only total 
ΔV = 132.2 mm3 and SRM = 0.75, versus pain-only total ΔV = 37.6 mm3 and 
SRM = 0.42). The pain-only group had equal or lower ∆V compared to non-
progressors in every region and compartment, although this effect may not be 
significant.   
[3] Medial versus lateral: Intriguingly, medial and lateral compartments in almost 
all groups show similar osteophyte ΔV and SRMs, despite subjects being selected 
based on medial JSL and specifically excluded for lateral JSL at BL. Given the 
higher cartilage structural damage in the medial compartment at BL, it would be 
expected that the medial compartment would show significantly greater 
osteophyte ΔV than lateral compartment. However, all subject groups show a 
similar medial ΔV and lateral ΔV, with perhaps the exception of JSL-only 
progressors. The JSL + pain and JSL-only groups are more consistent with the 
earlier trend of increased osteophyte ΔV in areas with JSL, but the ΔV and SRMs 
are fairly close (e.g. JSL+pain medial ΔV = 61.7 mm3 compared to JSL+pain 
lateral ΔV = 56.4 mm3, with only ~5 mm3 difference in volume).  
[4] Femoral versus tibial: the femoral regions and compartments showed higher ΔV 
and somewhat higher SRM compared to the tibia (e.g. all groups femoral ΔV = 
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49.7 mm3 and SRM = 0.51, versus tibial ΔV = 11.6 mm3 and SRM = 0.44) but 
also a larger SD.   
[5] SRM: The results of all groups, JSL-only group, and JSL+pain group showed 
moderate to moderate-high responsiveness to change (all groups SRM = 0.35 – 
0.55, JSL-only SRM = 0.52 – 0.72, and JSL+pain SRM = 0.42 – 0.68). Pain-only 
and non-progressor groups showed low to low-moderate SRMs (pain-only SRM 
= 0.10 – 0.45 and non-progressor SRM = 0.21 – 0.40).  
Finally, Table 6 shows the adjusted OR, 95% CI, and p-value for the three 
case/control statuses.  
 
Table 6: Adjusted odds ratios and 95% confidence interval for three case/control 
statuses: 1) radiographic + pain vs. no radiographic + pain progression, 2) radiographic vs. no 
radiographic progression, and 3) pain vs. no pain progression. 1 p < 0.001, 2 p < 0.05  
  
[1] Radiographic + pain progression versus no radiographic + pain progression: 
∆V is moderately associated with cartilage degeneration and pain together. 
Femoral regions (MF OR = 1.53, LF OR = 1.32) show a stronger effect than tibial 
regions (MT OR = 1.18, LT OR = 1.26). Medial (OR = 1.44) and lateral (OR = 
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1.37) compartments again have similar outcomes, and are closer to the total knee 
OR (OR = 1.49) than the separate knee regions.  
[2] Radiographic progression versus no radiographic progression: ∆V is most 
strongly associated with radiographic progression alone, and all ORs were 
significant. Medial regions (MF OR = 2.12, MT OR =1.72, M OR = 2.25) show 
the highest association of osteophyte volume change with cartilage degeneration, 
which is again expected given subjects were chosen by medial JSL.   
[3] Pain progression versus no pain progression: ∆V has almost low or no 
statistically significant association with pain progression. MF ∆V showed a low 
significant association with pain progression (OR = 1.22).  
[4] Total knee ∆V: ORs are reflective of overall effect of the predictor in each 
group. Pearson correlation coefficients (not shown in table) revealed a good 
association of total knee ∆V with the individual knee regions, with these results: 




This study addressed three objectives: 1) providing further longitudinal validation 
of a semi-automated software tool by finding good responsiveness and reader time, 2) 
discovering a statistically significant association between an increase in osteophyte 
volume and JSL, and 3) finding no statistically significant association between an 
increase in osteophyte volume with pain progression.   
Software method validation  
Based on SRM values (Table 5), we found moderate to moderate-high 
responsiveness of the software for osteophyte volume change to all the combined 
subjects, as well as specifically to the JSL-only and JSL+pain groups. We found lower 
but still meaningful responsiveness for the pain-only and non-progressor groups. Trends 
include increased sensitivity to femoral locations over tibial locations, as well as similar 
results in the lateral and medial compartments.   
Additionally, the semi-automated nature of the software made analysis rapid 
compared to non-software methods. That average reader time per scan was 10 minutes. 
Given that this study examined 18 slices per scan of the tibiofemoral joint at two time 
points for 505 subjects, this amounted to 18,180 slices finished over several months.   
These results further validate the efficacy of a semi-automated quantitative knee 
MRI software method, which may have utility in future studies that require fast and 
efficient quantification of osteophyte volume for KOA research.   
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Osteophyte volume change and JSL  
Overall, joint space loss was moderately and significantly associated with 
osteophyte volume change. JSL-only groups showed the highest change in osteophyte 
volume, and radiographic groups compared to the non-radiographic groups revealed the 
strongest adjusted OR values.  
Several patterns emerged. First, it is noteworthy that, although subjects for this 
cohort were selected based on the presence of medial JSL, since lateral compartment 
osteophyte ΔV and SRM were showed similar values to medial compartment osteophyte 
ΔV and SRM. Since we found the earlier trend of increased osteophyte ΔV correlating 
with increased cartilage loss, it is remarkable that the lateral knee compartment – which 
had a lower BL JSN than the medial compartment given the subject selection process – 
had almost equal osteophyte growth as the medial compartment, challenging the 
hypothesis that JSL on one side of the knee causes ipsilateral osteophyte growth (i.e. 
stabilizing the knee on the side where there is loss of articular cartilage) (Faschingbauer 
et al., 2015). Still, the JSL-only group is consistent the earlier trend of increased ΔV in 
areas with JSL.  
Given that a previous study found higher osteophyte scores increased risk of 
ipsilateral cartilage JSL progression (e.g. lateral osteophytes increased risk of lateral JSL) 
and decreased the risk of contralateral JSL progression, this is an interesting finding 
(Felson et al., 2004). However, these associations were attenuated by the presence of 
knee varus-valgus malalignment (Felson et al., 2004). It would be fruitful to further 
investigate the effect of KOA osteophyte presence and size based on knee compartment.  
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Second, the osteophyte ∆V, SRM, and ORs for the JSL+pain group were 
consistently the same or less than the JSL-only group. The presence of pain progression 
dilutes the moderately strong association of osteophyte growth with joint space 
narrowing, which could include both articular and meniscal cartilage loss. This is 
intriguing since clinically, cartilage loss combined with knee pain is a more severe form 
of KOA than cartilage loss alone, which makes it difficult to use osteophyte volume 
change as a unilateral marker of increased KOA severity.  
Third, femoral knee regions showed greater ∆V and SRM but larger SD than 
tibial compartments, indicating a higher magnitude and range of osteophyte volume 
change over time. Knowing the higher responsiveness and sensitivity to change of the 
femoral change may allow future studies to concentrate measurements in that 
compartment as a substitute for the entire joint.  
Fourth, the total knee results for ∆V, SRM, and OR were reflective of results in 
other knee compartments and regions. As indicated by the correlation coefficients, total 
knee change was a good stand-in for MF, MT, LF, and LT regions (r = 0.65 – 0.79). 
Also, total knee measurements tended to fall in the middle of other values, so it may be 
useful as a summary measurement on its own.  
Osteophyte volume change and pain progression  
It is interesting to note that the pain-only progressor group showed the least total 
ΔV out of all the groups, including the control non-progressor group, although the 
difference is only clearly significant between the pain-only group and JSL groups. 
Overall, both pain progressor groups showed no positive association with increased 
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osteophyte ΔV. Non-progressors, by definition, showed less KOA clinical progression 
than all other groups, but they did not have the smallest amount of osteophyte growth. 
This may support a hypothesis that osteophytes may only act as a marker of nearby 
cartilage loss, and other factors are more directly responsible for causing or alleviating 
knee pain during KOA progression.   
Pain progression also showed low or no statistically significant association with 
osteophyte volume growth based on adjusted ORs. Given some contradictory evidence 
from previous studies, it is difficult to infer the role of osteophytes in knee pain, the many 
factors influencing the presence and perception of pain by patients with KOA.  
 
Conclusion  
In conclusion, these results may shed light on the role of osteophytes in OA 
cartilage degeneration. We found that osteophyte volume is moderately associated with 
structural worsening of KOA, but less so with pain progression. Also, it is osteophyte 
growth in the lateral compartment of the tibiofemoral weight-bearing region is associated 
with JSL in the medial compartment, showing a contralateral rather than ipsilateral 
association between osteophytosis and JSL.  
There were several limitations to this study. First, software calculations of 
osteophyte volume were localized to a 2.5 cm weight-bearing area in the knee joint.  
Although this area was shown to be sensitive to whole-joint osteophyte growth, 
some KOA-related volume change may be unaccounted for. However, given that we used 
data from a longitudinal study and measured the same knee joint location in baseline and 
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24-months, the relative change in osteophyte volume between subregions and 
compartments should not be affected. Second, the current analysis in this thesis is based 
on 505 subjects out of the 600 subjects in FNIH OA Project case-control sample. 
However, these findings show significant results that are similar to an earlier preliminary 
analysis of 289 subjects from the same study sample (Yin 2016).  
Further research using this quantitative MRI software would help clarify the role 
of osteophyte growth in KOA, given that this software allows for a more granular and 
sensitive measurement of osteophyte volume. A more highly-powered study examining 
the correlation between osteophyte volume, articular cartilage loss, and knee pain could 
further elucidate the function of osteophytes in KOA and their status as a possible 
imaging biomarker for the disease.  
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